CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
Abruzzese
E
E
Cantonetti
M
M
Morino
L
L
Orlandi
G
G
Tendas
A
A
Del Principe
M I
MI
Masi
M
M
Amadori
S
S
Orlandi
A
A
Anemona
L
L
Campione
Elena
E
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006402:Hematologic Diseases; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl